Last reviewed · How we verify
SUCCIMER
At a glance
| Generic name | SUCCIMER |
|---|---|
| Drug class | Lead Chelator [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1991 |
Approved indications
Common side effects
- Nausea, vomiting, diarrhea, appetite loss, hemorrhoidal symptoms, metallic taste in mouth
- Back pain, abdominal cramps, stomach pains, head pain, rib pain, chills, flank pain, fever, flu-like symptoms, heavy head/tired, head cold, headache, moniliasis
- Elevated ALT or AST, alkaline phosphatase, serum cholesterol
- Sore throat, rhinorrhea, nasal congestion, cough
- Papular rash, herpetic rash, rash, mucocutaneous eruptions, pruritis
- Drowsiness, dizziness, sensorimotor neuropathy, sleepiness, paresthesia
- Cloudy film in eye, ears plugged, otitis media, eyes watery
- Neutropenia, increased platelet count, eosinophilia
Drug interactions
- Laboratory Tests
- Other Chelation Therapies (e.g., CaNa2EDTA)
Key clinical trials
- Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy (PHASE1)
- Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study (PHASE2)
- Electrophysiological Study of the Functioning of Magnocellular Visual Pathway in Regular Cannabis Users (NA)
- The Individual Therapy for Patients With Wilson's Disease (EARLY_PHASE1)
- Treatment of Lead-Exposed Children Trial (PHASE3)
- Mercury Chelation to Treat Autism (PHASE2)
- Dimercaptosuccinic Acid (DMSA) Treatment of Children With Autism and Heavy Metal Toxicity (PHASE1, PHASE2)
- The Combined Effect of 2,3-Dimercaptosuccinic Acid and Multi-Nutrients on Children in Lead Poisoning
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |